Get the Stockscreener App
519.26
1.14%
5.87
After Hours:
519.26
Idexx Laboratories Inc stock is traded at $519.26, with a volume of 331.10K.
It is up +1.14% in the last 24 hours and down -5.59% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$513.39
Open:
$510.94
24h Volume:
331.10K
Relative Volume:
0.56
Market Cap:
$40.91B
Revenue:
$4.45B
Net Income/Loss:
$1.10B
P/E Ratio:
38.21
EPS:
13.591
Net Cash Flow:
$1.06B
1W Performance:
+1.49%
1M Performance:
-5.59%
6M Performance:
-9.81%
1Y Performance:
-16.00%
1-Day Range:
$507.01
$520.16
1-Week Range:
$506.22
$524.12
52-Week Range:
$500.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
519.26 | 40.45B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
675.00 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
224.49 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
412.56 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.79 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.37 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
IDEXX Laboratories stock falls 1.65 percent below USD 747 target - AD HOC NEWS
IDEXX Laboratories stock heads into the open after September 24 update - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History - Yahoo! Finance Canada
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Singapore
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
Should You Continue to Hold IDXX Stock in Your Portfolio? - TradingView
IDEXX Laboratories stock gains as revenue outlook meets premium valuation - AD HOC NEWS
IDEXX Laboratories stock heads into the open after a 1.16 percent gain - AD HOC NEWS
IDEXX Laboratories Acquires CoVetAI to Enhance Veterinary Software Ecosystem - globallegalchronicle.com
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories stock gains 1.16 percent as valuation holds - AD HOC NEWS
IDEXX Laboratories stock heads into the open after recent gains - AD HOC NEWS
IDEXX Laboratories stock gains after double digit Q2 growth and raised guidance - AD HOC NEWS
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof - DVM360
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets - Yahoo Finance
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference - Yahoo Finance
IDEXX Laboratories stock gains attention after CoVetAI deal and Stifel Buy rating - AD HOC NEWS
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics - Yahoo Finance
IDEXX Laboratories Inc | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
IDEXX Laboratories stock holds after Stifel keeps Buy rating - AD HOC NEWS
Why Is the Market Reassessing IDEXX Laboratories (IDXX)? - Kalkine Media
IDEXX Laboratories stock holds Stifel Buy rating after Q2 earnings beat - ad-hoc-news.de
Stifel reiterates Buy on IDEXX Laboratories stock citing vet survey By Investing.com - Investing.com Australia
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide - Yahoo Finance
IDEXX Laboratories stock heads into the open after a modest pullback - AD HOC NEWS
IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus - Yahoo Finance
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Vet Candy
IDEXX Laboratories stock gains as CoVetAI deal and new parasite tests bolster growth narrative - AD HOC NEWS
IDEXX Stock Gains Following the Acquisition of CoVet - TradingView
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection - PA Media
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $670 - Moomoo
IDEXX Laboratories (IDXX) Looks 19.8% Undervalued on GF Value™ - GuruFocus
IDEXX Laboratories Acquires Veterinary AI Software Firm CoVetAI - marketscreener.com
Press Release: IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Moomoo
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 38% Potential Upside For Investors - DirectorsTalk Interviews
IDXX - Finviz
IDEXX Laboratories stock gains as analysts lift targets - ad-hoc-news.de
IDEXX Laboratories stock reacts to insider share sale and recent earnings strength - ad-hoc-news.de
Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories - Benzinga
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock - The Motley Fool
Is IDEXX Laboratories Stock Underperforming the Dow? - inkl
Idexx Laboratories stock hits 52-week low at $517.00 By Investing.com - Investing.com Australia
IDEXX Laboratories (IDXX) director exercises options and sells 2,203 shares - Stock Titan
Idexx Laboratories stock hits 52-week low at $517.00 - Investing.com
IDEXX Laboratories stock heads into the open after a modest gain - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):